EGFR and non-small cell lung carcinoma: In the study ABC‐lung, atezolizumab plus bevacizumab and chemotherapy (pemetrexed or carboplatin/paclitaxel) showed benefit in NSCLC patients progressed on EGFR‐TKIs (ORR: 32%–47%, mPFS: 6.4–7.6 months) [30].